NACL Industries Limited has executed a Share Purchase Agreement on August 10, 2026, to divest its equity shareholding in Nasense Labs Private Limited, an associate company. The execution of this agreement marks the finalization of the proposed divestment, which was previously approved by the company's Board of Directors on July 22, 2026. This move signals a strategic shift in the company’s portfolio management regarding its associate investments.

The intimation was submitted to the BSE Limited and the National Stock Exchange of India Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rajesh Mukhija, Company Secretary, signed the disclosure letter dated August 10, 2026, confirming that the Share Purchase Agreement was executed on Monday, August 10, 2026, for the transfer of the equity stake.

Transaction Details

The divestment involves the transfer of NACL Industries Limited's entire equity shareholding in Nasense Labs Private Limited. While the specific financial terms, such as the consideration amount or valuation metrics, were not disclosed in this regulatory filing, the completion of the Share Purchase Agreement indicates that the commercial terms have been mutually agreed upon by both parties.

Strategic Context

Nasense Labs Private Limited is classified as an associate company of NACL Industries Limited. The decision to divest suggests a potential restructuring of the group’s investment holdings or a strategic realignment away from this specific business vertical. The initial intimation regarding the board approval was issued on July 22, 2026, providing shareholders with prior notice of the intended exit strategy.

What the Numbers Show

While the filing does not provide quantitative financial data regarding the divestment proceeds or the carrying value of the stake, the timeline between board approval and agreement execution is notable. The process concluded within approximately three weeks, indicating a streamlined negotiation phase. Investors should monitor future financial statements for the impact of this divestment on the company’s consolidated revenue and net profit, particularly if the associate contributed significantly to these metrics in prior periods.

NACL Industries Limited reported a standalone net profit of ₹23.57 crore for the quarter ended June 30, 2026, marking a 64.8% increase from ₹14.30 crore in the corresponding period of the previous year. Revenue from operations for Q1FY27 stood at ₹382.25 crore, while total income was ₹384.26 crore. The Board of Directors approved the unaudited financial results on July 22, 2026.

Financial Performance

The company's EBITDA for the quarter stood at ₹414 million, up from ₹381 million in the same period last year, reflecting improved operational efficiency. EBITDA margin expanded meaningfully to 10.8% from 8.51% on a year-on-year basis. On a consolidated basis, net profit rose to ₹20.84 crore from ₹13.04 crore in Q1FY26, while consolidated revenue from operations was ₹383.33 crore compared to ₹448.36 crore in the prior year period. The basic and diluted earnings per share (EPS) for the standalone entity were recorded at ₹1.01 for the quarter, up from ₹0.66 in the same period last year.

The table below summarises the key financial metrics for the quarter:

Strategic Divestment

The Board approved the proposal to divest the company's entire equity stake in Nasense Labs Private Limited, an associate company. The stake will be sold to Mr. Kanumuru Satyanarayana Raju for a total consideration of ₹8,15,29,967. The transaction is expected to be completed within the next three months, subject to the fulfilment of terms and conditions outlined in the Share Purchase Agreement. Post-completion, Nasense Labs Private Limited will cease to be an associate company of NACL Industries Limited.

Operational Details

The unaudited financial results were reviewed by M/s. S R Batliboi & Associates, Statutory Auditors of the company, who issued an unmodified conclusion. The company also reported that funds raised through a rights issue in December 2025 have been utilised for the intended purposes, with an unutilised amount of ₹2,445 lakhs deposited in an earmarked bank account. Additionally, the company allotted 65,000 equity shares during the quarter pursuant to the exercise of stock options.